Regulatory Guidance Monthly Review - February 2024
Stay up-to-date with the latest regulatory guidance updates from the FDA in February 2024. From clinical trial regulations to drug approvals, this...
4 min read
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.
FDA Final Guidance:
Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics: Guidance for Industry (published 14-Jun-2024)
Download FDA Guidance
Diabetic Foot Infections: Developing Drugs for Treatment (published 17-Jun-2024)
Download FDA Guidance
Facility Readiness: Goal Date Decisions Under GDUFA (published 18-Jun-2024)
Download FDA Guidance
Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection: Guidance for Industry (published 20-Jun-2024)
Download FDA Guidance
FDA Draft Guidance:
Processes and Practices Applicable to Bioresearch Monitoring Inspections: Draft Guidance for Industry (published 05-Jun-2024)
Draft FDA Guidance
Standardized Format for Electronic Submission for Marketing Applications Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for Center of Biologics Evaluation and Research Submissions (published 05-Jun-2024)
Draft FDA Guidance
Considerations in Demonstrating Interchangeability With a Reference Product: Update (published 21-Jun-2024)
Draft FDA Guidance
Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies: Draft Guidance for Industry (published 26-Jun-2024)
Draft FDA Guidance
Essential Drug Delivery Outputs for Devices Intended to Deliver Drugs and Biological Products: Draft Guidance for Industry (published 28-Jun-2024)
Draft FDA Guidance
Monthly FDA Approvals
Approval Date: 06/04/2024
Drug Name: TERIPARATIDENDA #218771
Active Ingredients: TERIPARATIDE
Submission Classification: Type 5 - New Formulation or New Manufacturer
Review Priority: Standard
Company: ALMAJECT
Approval Date: 06/06/2024
Drug Name: RYTELONDA #217779
Active Ingredients: IMETELSTAT SODIUM
Submission Classification: Type 1 - New Molecular Entity
Review Priority: Standard
Company: GERON
Approval Date: 06/10/2024
Drug Name: IQIRVONDA #218860
Active Ingredients: ELAFIBRANOR
Submission Classification: Type 1 - New Molecular Entity
Review Priority: Priority
Company: IPSEN
Approval Date: 06/17/2024
Drug Name: VIGAFYDENDA #217684
Active Ingredients: VIGABATRIN
Submission Classification:
Review Priority: Standard
Company: PYROS PHARMS
Approval Date: 06/18/2024
Drug Name: SOFDRANDA #217347
Active Ingredients: SOFPIRONIUM BROMIDE
Submission Classification: Type 1 - New Molecular Entity
Review Priority: Standard
Company: BOTANIX SB
Approval Date: 06/20/2024
Drug Name: PIASKYBLA #761388
Active Ingredients: CROVALIMAB-AKKZ
Submission Classification:
Review Priority:
Company: GENENTECH INC
Approval Date: 06/25/2024
Drug Name: TEPYLUTENDA #216984
Active Ingredients: THIOTEPA
Submission Classification: Type 3 - New Dosage Form
Review Priority: Standard
Company: SHORLA
Approval Date: 06/28/2024
Drug Name: PEMETREXEDNDA #210661
Active Ingredients: PEMETREXED
Submission Classification: Type 2 - New Active Ingredient
Review Priority: Standard
Company: APOTEX INC
Approval Date: 06/28/2024
Drug Name: CHEWTADZYNDA #218527
Active Ingredients: TADALAFIL
Submission Classification: Type 3 - New Dosage Form
Review Priority: Standard
Company: B BETTER LLC
Approval Date: 06/28/2024
Drug Name: NYPOZIBLA #761126
Active Ingredients: FILGRASTIM-TXID
Submission Classification:
Review Priority:
Company: TANVEX BIOPHARMA USA INC
Approval Date: 06/28/2024
Drug Name: PYZCHIVABLA #761373
Active Ingredients: USTEKINUMAB-TTWE
Submission Classification:
Review Priority:
Company: SAMSUNG BIOEPIS CO LTD
Approval Date: 06/28/2024
Drug Name: AHZANTIVEBLA #761378
Active Ingredients: AFLIBERCEPT
Submission Classification:
Review Priority:
Company: FORMYCON AG
Approval Date: 06/28/2024
Drug Name: PYZCHIVABLA #761425
Active Ingredients: USTEKINUMAB-TTWE
Submission Classification:
Review Priority:
Company: SAMSUNG BIOEPIS CO LTD
Upcoming Advisory Board Meetings
07/25/2024 - Oncologic Drugs Advisory Committee Meeting- 09:00 AM EDT to 02:15 PM EDT EDT
Experts, FDA officials discuss future of clinical trials (published 03-Jun-2024)
Read Article on RAPS.org
AAM seeks clarity, leeway in BA/BE studies guidance (published 03-Jun-2024)
Read Article on RAPS.org
FDA official discusses best practice for requesting feedback for combination products (published 04-Jun-2024)
Read Article on RAPS.org
FDA issues draft guidances covering BIMO inspections (published 05-Jun-2024)
Read Article on RAPS.org
FDA official offers compliance updates, discusses enforcement misperceptions (published 06-Jun-2024)
Read Article on RAPS.org
Industry experts peel back the curtain on user fee negotiations (published 07-Jun-2024)
Read Article on RAPS.org
Regulators launch two ACT EU advice pilots to promote clinical research in Europe (published 10-Jun-2024)
Read Article on RAPS.org
Experts advise against prescriptive FDA policies for regulating AI (published 10-Jun-2024)
Read Article on RAPS.org
ICH announces forthcoming documents on nitrosamine impurities, RWD (published 12-Jun-2024)
Read Article on RAPS.org
MDCG aims to harmonize adverse events reports for surgical mesh in the EU (published 13-Jun-2024)
Read Article on RAPS.org
FDA, Health Canada, MHRA release guiding principles on transparency for machine learning medical devices (published 14-Jun-2024)
Read Article on RAPS.org
Study: Women underrepresented in clinical trials of medical devices (published 17-Jun-2024)
Read Article on RAPS.org
FDA finalizes guidance on drug development for diabetic foot infections (published 18-Jun-2024)
Read Article on RAPS.org
DIA: Pharma expert offers advice on AI best practices for industry (published 18-Jun-2024)
Read Article on RAPS.org
DIA: Marks questions the need for new conditional approval pathway (published 20-Jun-2024)
Read Article on RAPS.org
Stakeholders request elaboration, consistency in FDA’s non-interventional RWE studies guidance (published 20-Jun-2024)
Read Article on RAPS.org
Industry officials report mixed experiences with recent FDA pilot programs (published 21-Jun-2024)
Read Article on RAPS.org
FDA publishes LDT rule ‘CliffsNotes’ in guidance for small companies (published 24-Jun-2024)
Read Article on RAPS.org
FDA official tells CGT developers to leverage multiple meeting opportunities with agency (published 24-Jun-2024)
Read Article on RAPS.org
EMA official updates on EU clinical trial transparency rules (published 25-Jun-2024)
Read Article on RAPS.org
FDA issues diversity action plan draft guidance (published 26-Jun-2024)
Read Article on RAPS.org
Stakeholders urge FDA to strengthen guidance on biosimilars promotions, stop bad actors (published 27-Jun-2024)
Read Article on RAPS.org
EMA officials discuss expedited approval pathways, scientific advice mechanisms
Read Article on RAPS.org
- Review the recording from our webinar: Align New Oncology Drug Development with FDA's Project FrontRunner
- Learn how Veristat experts can help you better plan your decentralized clinical trials: Adopting Decentralized Clinical Trials
- Read our infographic to learn more about the different types of meetings under BsUFA FDA Meeting Types for Biosimilar Products
- Download the Infographic explaining the Types of FDA Meetings with CDER and CBER
Regulatory Guidance Monthly Review - December 2023
Stay up-to-date with the latest regulatory guidance updates from the FDA in December 2023. From clinical trial regulations to drug approvals, this...
Regulatory Guidance Monthly Review - October 2023
Stay up-to-date with the latest regulatory guidance updates from the FDA in October 2023. From clinical trial regulations to drug approvals, this...